Literature DB >> 7684042

Regulation of insulin-like growth factor-binding-protein-1, 2, 3, 4, 5, and 6: synthesis, secretion, and gene expression in estrogen receptor-negative human breast carcinoma cells.

M S Sheikh1, Z M Shao, A Hussain, D R Clemmons, J C Chen, C T Roberts, D LeRoith, J A Fontana.   

Abstract

Insulin-like growth-factors I and II (IGF-I, II) are potent mitogens for breast carcinoma proliferation. In extracellular fluids, most of the IGF-I and II is associated with specific IGF-binding proteins (IGFBPs). The role of these IGFBPs in IGF action is still not clear, but it has been demonstrated that these proteins may either enhance or inhibit IGF-mediated cellular effects. Synthesis and secretion of IGFBPs have been demonstrated in breast carcinoma cells. In this study, we examined retinoic acid (RA) and IGF-I modulation of IGFBP mRNA and IGFBP levels in two ER-negative human breast carcinoma cell lines. Treatment of MDA-MB-231 and MDA-MB-468 cells with RA increased the levels in conditioned media of a M(r) 42-46-kDa IGFBP, which was immunoprecipitated by an IGFBP-3 antibody. IGF-I also increased the accumulated levels of IGFBP-3 in the conditioned media of both cell lines. Both cell lines expressed high basal levels of IGFBP-3 mRNA; the addition of RA increased IGFBP-3 mRNA levels by 1.5-fold, whereas the addition of IGF-I had no effect on IGFBP-3 mRNA levels in either cell line. The difference in the magnitude of the RA enhancement of IGFBP-3 mRNA levels (1.5-fold) and RA stimulation of IGFBP-3 levels in conditioned media (3.5-4-fold) suggests that some of the effect of RA is at a posttranscriptional level. IGF-I increased the levels of IGFBP-2 and IGFBP-5 in conditioned media by greater than tenfold but had no effect on IGFBP-2 and IGFBP-5 mRNA levels, again suggesting the involvement of posttranscriptional controls. Pretreatment of MDA-MB-468 and MDA-MB-231 cells with IGF-I receptor antibody (alpha IR3) blocked the IGF-I effect on IGFBP-3 levels in the media in both cell lines and IGFBP-2 and IGFBP-5 secreted levels in MDA-MB-468 cell conditioned media. The addition of RA also blocked IGF-I stimulation of IGFBP-2 and IGFBP-5 levels. Cycloheximide treatment completely blocked the RA and/or IGF-I-mediated modulation of these binding proteins, suggesting that these agents enhance IGFBP-3, IGFBP-2, and IGFBP-5 synthesis and consequent secretion. MDA-MB-468 cells expressed IGFBP-5 mRNA, whereas both MDA-MB-231 and MDA-MB-468 expressed IGFBP-6 mRNA. RA enhanced IGFBP-6 gene expression by threefold in MDA-MB-231 cells, whereas IGF-1 had no effect on IGFBP-6 gene expression in either cell line.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7684042     DOI: 10.1002/jcp.1041550314

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  15 in total

Review 1.  Cellular actions of insulin-like growth factor binding proteins.

Authors:  R J Ferry; L E Katz; A Grimberg; P Cohen; S A Weinzimer
Journal:  Horm Metab Res       Date:  1999 Feb-Mar       Impact factor: 2.936

Review 2.  Genetics, chemistry, and function of the IGF/IGFBP system.

Authors:  P F Collett-Solberg; P Cohen
Journal:  Endocrine       Date:  2000-04       Impact factor: 3.633

3.  All-trans retinoic acid converts E2F into a transcriptional suppressor and inhibits the growth of normal human bronchial epithelial cells through a retinoic acid receptor- dependent signaling pathway.

Authors:  H Y Lee; D F Dohi; Y H Kim; G L Walsh; U Consoli; M Andreeff; M I Dawson; W K Hong; J M Kurie
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

4.  Expression of IGF-II, IGFBP-2, -5, and -6 in meningiomas with different brain invasiveness.

Authors:  Ann-Christin Sandberg Nordqvist; Tiit Mathiesen
Journal:  J Neurooncol       Date:  2002-03       Impact factor: 4.130

5.  Cell polarity of the insulin-like growth factor system in human intestinal epithelial cells. Unique apical sorting of insulin-like growth factor binding protein-6 in differentiated human colon cancer cells.

Authors:  M Remacle-Bonnet; F Garrouste; F el Atiq; J Marvaldi; G Pommier
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

6.  Disease evidence for IGFBP-2 as a key player in prostate cancer progression and development of osteosclerotic lesions.

Authors:  David J Degraff; Adam A Aguiar; Robert A Sikes
Journal:  Am J Transl Res       Date:  2009-01-20       Impact factor: 4.060

7.  A novel antitumor activity of deguelin targeting the insulin-like growth factor (IGF) receptor pathway via up-regulation of IGF-binding protein-3 expression in breast cancer.

Authors:  Young-Ah Suh; Jai-Hyun Kim; Myung A Sung; Hye-Jin Boo; Hye Jeong Yun; Sun-Hye Lee; Hyo-Jong Lee; Hye-Young Min; Young-Ger Suh; Kyu-Won Kim; Ho-Young Lee
Journal:  Cancer Lett       Date:  2013-01-21       Impact factor: 8.679

8.  Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3.

Authors:  V Hwa; Y Oh; R G Rosenfeld
Journal:  Endocrine       Date:  1997-06       Impact factor: 3.633

9.  Role of insulin-like growth factor-binding protein 5 (IGFBP5) in organismal and pancreatic beta-cell growth.

Authors:  Catherine E Gleason; Yun Ning; Tara P Cominski; Rana Gupta; Klaus H Kaestner; John E Pintar; Morris J Birnbaum
Journal:  Mol Endocrinol       Date:  2009-11-06

Review 10.  Insulin-like growth factor-binding protein-5 (IGFBP-5): a critical member of the IGF axis.

Authors:  James Beattie; Gordon J Allan; Jennifer D Lochrie; David J Flint
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.